Analyst Price Target is $51.75
▲ +228.15% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Scribe Therapeutics in the last 3 months. The average price target is $51.75, with a high forecast of $60.00 and a low forecast of $37.00. The average price target represents a 228.15% upside from the last price of $15.77.
Current Consensus is
Moderate Buy
The current consensus among 6 contributing investment analysts is to moderate buy stock in Scribe Therapeutics. This rating has held steady since August 2026, when it changed from a Buy consensus rating.